UVA Cancer Center, an NCI Comprehensive Cancer Center | Strategic Alliance Partners

August 28, 2018

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.

August 24, 2018

Ryan D. Gentzler, MD, highlights how chemotherapy remains a critical component of the metastatic non–small cell lung cancer treatment paradigm.

August 22, 2018

Richard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).

August 21, 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).

August 15, 2018

James Larner, MD, discusses the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with non–small cell lung cancer.

January 31, 2018

Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.

December 11, 2017

Due to great progress in alternative donor transplants, almost all transplant-eligible patients, up to age 75 years, in 2017 will be able to find a suitable donor and proceed to transplant, a major advance over the past 10 years.

May 04, 2017

The University of Virginia Cancer Center has developed a new method for delivering radiation therapy along with less invasive surgery in a more precise and personalized manner.

April 11, 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

March 24, 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

February 03, 2017

The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.

January 18, 2017

Robert Dreicer, MD, associate director for clinical research and deputy director of the University of Virginia Cancer Center, discusses the questions that surround radium-223.

October 21, 2016

In 2014, under the leadership of UVA Executive Vice President Richard P. Shannon, MD, the Be Safe initiative was developed to deliver the highest-quality of advanced healthcare to patients, and emphasizes 3 main areas.

May 12, 2016

Robert Dreicer, MD, provides insight on the IMvigor 210 study and how atezolizumab will dramatically change the treatment paradigm for patients with metastatic urothelial carcinoma, who have a severe unmet need.

April 21, 2016

A collaborative patient reported outcome-based care approach resulted in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients.

May 08, 2014

Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis